Aytu BioPharma Announces Initiation of the AR101 PREVEnt Trial for the Treatment of Vascular Ehlers-Danlos Syndrome
The specialty pharmaceutical company, AytuBio Pharma, announced the initiation of the global Phase 3 PREVEnt (Prevention of Ruptures with Enzastaurin for Vascular Ehlers-Danlos Syndrome) clinical trial. This study will be investigating the ability of enzastaurin to reduce the severe complications of vascular Ehlers-Danlos syndrome (vEDS). There are currently no FDA-approved therapies for vEDS. What is the PREVEnt trial? The PREVEnt View page